OBJECTIVE: 11β-Hydroxysteroid dehydrogenase type I (11βHSD1) regenerates active cortisol from inert cortisone in adipose tissue. Elevated adipose tissue 11βHSD1 activity is observed in obese humans and rodents, where it is linked to obesity and its metabolic consequences. Menopause is also associated with increased abdominal fat accumulation, suggesting that estrogen is also important in adipose tissue metabolism. The purpose of this current study was to establish whether estrogen signaling through estrogen receptor α (ER-α) and estrogen receptor β (ER-β) could influence 11βHSD1 in premenopausal and postmenopausal adipose tissues. METHODS: Nineteen premenopausal (aged 26 ± 5 y; body mass index, 23.6 ± 1.6 kg/m) and 23 postmenopausal (aged 63 ± 4 y; body mass index, 23.4 ± 1.9 kg/m) healthy women were studied. Subcutaneous adipose tissue biopsies and fasting venous blood samples were taken. Body composition was measured by bioelectrical impedance analysis. Human Simpson-Golabi-Behmel syndrome adipocyte cells were treated with ER-α- and ER-β-specific agonists for 24 hours. Basic anthropometric data, serum 17β-estradiol and progesterone concentrations, ER-α and ER-β messenger RNA (mRNA) levels, and 11βHSD1 mRNA, protein, and activity levels were assessed. RESULTS: ER-β and 11βHSD1, but not ER-α, mRNAs were significantly increased in adipose tissue from postmenopausal women compared with premenopausal women. ER-β had a significant positive correlation with the mRNA level of 11βHSD1 in adipose tissue from premenopausal and postmenopausal women. This association between ER-β and 11βHSD1 was greatest in adipose tissue from postmenopausal women. In human Simpson-Golabi-Behmel syndrome adipocytes, diarylpropiolnitrile, a selective ER-β agonist, increased 11βHSD1 mRNA, protein, and activity levels. CONCLUSIONS: We conclude that, in adipose tissue, ER-β-mediated estrogen signaling can up-regulate 11βHSD1 and that this may be of particular importance in postmenopausal women.
OBJECTIVE: 11β-Hydroxysteroid dehydrogenase type I (11βHSD1) regenerates active cortisol from inert cortisone in adipose tissue. Elevated adipose tissue 11βHSD1 activity is observed in obesehumans and rodents, where it is linked to obesity and its metabolic consequences. Menopause is also associated with increased abdominal fat accumulation, suggesting that estrogen is also important in adipose tissue metabolism. The purpose of this current study was to establish whether estrogen signaling through estrogen receptor α (ER-α) and estrogen receptor β (ER-β) could influence 11βHSD1 in premenopausal and postmenopausal adipose tissues. METHODS: Nineteen premenopausal (aged 26 ± 5 y; body mass index, 23.6 ± 1.6 kg/m) and 23 postmenopausal (aged 63 ± 4 y; body mass index, 23.4 ± 1.9 kg/m) healthy women were studied. Subcutaneous adipose tissue biopsies and fasting venous blood samples were taken. Body composition was measured by bioelectrical impedance analysis. HumanSimpson-Golabi-Behmel syndrome adipocyte cells were treated with ER-α- and ER-β-specific agonists for 24 hours. Basic anthropometric data, serum 17β-estradiol and progesterone concentrations, ER-α and ER-β messenger RNA (mRNA) levels, and 11βHSD1 mRNA, protein, and activity levels were assessed. RESULTS: ER-β and 11βHSD1, but not ER-α, mRNAs were significantly increased in adipose tissue from postmenopausal women compared with premenopausal women. ER-β had a significant positive correlation with the mRNA level of 11βHSD1 in adipose tissue from premenopausal and postmenopausal women. This association between ER-β and 11βHSD1 was greatest in adipose tissue from postmenopausal women. In humanSimpson-Golabi-Behmel syndrome adipocytes, diarylpropiolnitrile, a selective ER-β agonist, increased 11βHSD1 mRNA, protein, and activity levels. CONCLUSIONS: We conclude that, in adipose tissue, ER-β-mediated estrogen signaling can up-regulate 11βHSD1 and that this may be of particular importance in postmenopausal women.
Authors: Nicholas M Morton; Janice M Paterson; Hiroaki Masuzaki; Megan C Holmes; Bart Staels; Catherine Fievet; Brian R Walker; Jeffrey S Flier; John J Mullins; Jonathan R Seckl Journal: Diabetes Date: 2004-04 Impact factor: 9.461
Authors: Marie L Misso; Christina Jang; Jennifer Adams; Jane Tran; Yoko Murata; Robin Bell; Wah Chin Boon; Evan R Simpson; Susan R Davis Journal: Menopause Date: 2005-03 Impact factor: 2.953
Authors: Eva Rask; Brian R Walker; Stefan Söderberg; Dawn E W Livingstone; Mats Eliasson; Owe Johnson; Ruth Andrew; Tommy Olsson Journal: J Clin Endocrinol Metab Date: 2002-07 Impact factor: 5.958
Authors: Kerry J McInnes; Kristy A Brown; Kevin C Knower; Ashwini L Chand; Colin D Clyne; Evan R Simpson Journal: Breast Cancer Res Treat Date: 2008-01-05 Impact factor: 4.872
Authors: Wei Shen; Mark Punyanitya; Analiza M Silva; Jun Chen; Dympna Gallagher; Luís B Sardinha; David B Allison; Steven B Heymsfield Journal: Nutr Metab (Lond) Date: 2009-04-16 Impact factor: 4.169
Authors: Jay W Porter; Jillian L Barnas; Rebecca Welly; Nicole Spencer; James Pitt; Victoria J Vieira-Potter; Jill A Kanaley Journal: Obesity (Silver Spring) Date: 2020-07-31 Impact factor: 5.002
Authors: Animesh N Sharma; Paul Aoun; Jean R Wigham; Suanne M Weist; Johannes D Veldhuis Journal: Am J Physiol Regul Integr Comp Physiol Date: 2014-02-26 Impact factor: 3.619
Authors: Young-Min Park; Christopher Erickson; Dan Bessesen; Rachael E Van Pelt; Kimberly Cox-York Journal: Steroids Date: 2017-03-10 Impact factor: 2.668
Authors: Young-Min Park; Rocio I Pereira; Christopher B Erickson; Tracy A Swibas; Kimberly A Cox-York; Rachael E Van Pelt Journal: PLoS One Date: 2017-05-04 Impact factor: 3.240
Authors: Young-Min Park; Rocio I Pereira; Christopher B Erickson; Tracy A Swibas; Chounghun Kang; Rachael E Van Pelt Journal: Menopause Date: 2017-07 Impact factor: 2.953
Authors: Anna J Anderson; Ruth Andrew; Natalie Z Homer; Gregory C Jones; Kenneth Smith; Dawn E Livingstone; Brian R Walker; Roland H Stimson Journal: J Clin Endocrinol Metab Date: 2016-07-26 Impact factor: 5.958